drugset / Trial / NCT00100971

Vaccine Therapy in Treating Patients With Acute Myeloid Leukemia

NCT00100971

Phase 1 Terminated 9 enrolled Boston Medical Center
Treatment

Summary

RATIONALE: Vaccines made from a person's white blood cells and cancer cells may make the body build an effective immune response to kill cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with acute myeloid leukemia.

Timeline

Start
2004-04
Primary completion
2007-03
Completion
2007-03

Drugs

EvaluationDrugModalityDoseRoute
Subject autologous tumor cell vaccine Vaccine Subcutaneous
Subject therapeutic autologous dendritic cells Vaccine Subcutaneous

Indications